Citations

Clear

6274 citation(s) found for "To, Andrew".

Sarcopenia: A Time for Action. An SCWD Position Paper
Bauer, Jürgen M. , Morley, John E. , Schols, Annemie M.W.J. , Ferrucci, Luigi , Cruz‐Jentoft, Alfonso J. , Dent, Elsa , Crawford, Jeffrey A., Doehner, Wolfram , Jatoi, Aminah , Kalantar‐Zadeh, Kamyar, Landi, Francesco , Laviano, Alessandro , Muscaritoli, Maurizio , Prado, Carla M. , Strasser, Florian, Haehling, Stephan von , Kalantar-Zadeh, Kamyar , Ferrucci, Luigi , Baracos, Vickie E. , Heymsfield, Steven B. , Lainščak, Mitja , Mancuso, Michelangelo , Coats, Andrew J.S. , Anker, Stefan D. , Doehner, Wolfram , Kalantar-Zadeh, Kamyar

Mayo Clinic

Journal of Cachexia, Sarcopenia and Muscle | September 16, 2019 | Volume: 10 | Issue: 5 | Pages: 956-961

10.1002/jcsm.12483 | PMID 31523937 Get It

Abstract The term sarcopenia was introduced in 1988. The original definition was a “muscle loss” of the appendicular muscle mass in the older people as measured by dual energy x‐ray absorptiometry (DXA). In 2010, the definition was altered to be low muscle mass together with low muscle function and this was agreed upon as reported in a number of consensus papers. The Society of Sarcopenia, Cachexia and Wasting Disorders supports the recommendations of more recent consensus conferences, i.e. that rapid screening, such as with the SARC‐F questionnaire, should be utilized with a formal diagnosis being made by measuring grip strength or chair stand together with DXA estimation of appendicular muscle mass (indexed for height2). Assessments of the utility of ultrasound and creatine dilution techniques are ongoing. Use of ultrasound may not be easily reproducible. Primary sarcopenia is aging associated (mediated) loss of muscle mass. Secondary sarcopenia (or disease‐related sarcopenia) has predominantly focused on loss of muscle mass without the emphasis on muscle function. Diseases that can cause muscle wasting (i.e. secondary sarcopenia) include malignant cancer, COPD, heart failure, and renal failure and others. Management of sarcopenia should consist of resistance exercise in combination with a protein intake of 1 to 1.5 g/kg/day. There is insufficient evidence that vitamin D and anabolic steroids are beneficial. These recommendations apply to both primary (age‐related) sarcopenia and secondary (disease related) sarcopenia. Secondary sarcopenia also needs appropriate treatment of the underlying disease. It is important that primary care health professionals become aware of and make the diagnosis of age‐related and disease‐related sarcopenia. It is important to address the risk factors for sarcopenia, particularly low physical activity and sedentary behavior in the general population, using a life‐long approach. There is a need for more clinical research into the appropriate measurement for muscle mass and the management of sarcopenia. Accordingly, this position statement provides recommendations on the management of sarcopenia and how to progress the knowledge and recognition of sarcopenia.
A Machine Learning-Based Triage Tool for Children With Acute Infection in a Low Resource Setting*
Kwizera, Arthur , Kissoon, Niranjan , Musa, Ndidiamaka, Urayeneza, Olivier, Mujyarugamba, Pierre , Harmon, Lori, Farmer, Joseph C. , Dünser, Martin W. , Meier, Jens , Patterson, Andrew J.

Mayo Clinic

Pediatric Critical Care Medicine | September 13, 2019 | Volume: 20 | Issue: 12 | Pages: e524-e530

10.1097/pcc.0000000000002121 | PMID 31805020 Get It

Objectives: To deploy machine learning tools (random forests) to develop a model that reliably predicts hospital mortality in children with acute infections residing in low- and middle-income countries, using age and other variables collected at hospital admission. Design: Post hoc analysis of a single-center, prospective, before-and-after feasibility trial. Setting: Rural district hospital in Rwanda, a low-income country in Sub-Sahara Africa. Patients: Infants and children greater than 28 days and less than 18 years of life hospitalized because of an acute infection. Interventions: None. Measurements and Main Results: Age, vital signs (heart rate, respiratory rate, and temperature) capillary refill time, altered mental state collected at hospital admission, as well as survival status at hospital discharge were extracted from the trial database. This information was collected for 1,579 adult and pediatric patients admitted to a regional referral hospital with an acute infection in rural Rwanda. Nine-hundred forty-nine children were included in this analysis. We predicted survival in study subjects using random forests, a machine learning algorithm. Five prediction models, all including age plus two to five other variables, were tested. Three distinct optimization criteria of the algorithm were then compared. The in-hospital mortality was 1.5% (n = 14). All five models could predict in-hospital mortality with an area under the receiver operating characteristic curve ranging between 0.69 and 0.8. The model including age, respiratory rate, capillary refill time, altered mental state exhibited the highest predictive value area under the receiver operating characteristic curve 0.8 (95% CI, 0.78–0.8) with the lowest possible number of variables. Conclusions: A machine learning-based algorithm could reliably predict hospital mortality in a Sub-Sahara African population of 949 children with an acute infection using easily collected information at admission which includes age, respiratory rate, capillary refill time, and altered mental state. Future studies need to evaluate and strengthen this algorithm in larger pediatric populations, both in high- and low-/middle-income countries.
Neurochondrin neurological autoimmunity
Shelly, Shahar , Kryzer, Thomas J., Komorowski, Lars , Miske, Ramona , Anderson, Mark D. , Hinson, Shannon R., Lennon, Vanda A. , Pittock, Sean J. , Pittock, S J , Shahar, Shelly , Flanagan, Eoin P. , McKeon, Andrew

Mayo Clinic

Neurology Neuroimmunology & Neuroinflammation | September 11, 2019 | Volume: 6 | Issue: 6 | Pages: No page available

10.1212/nxi.0000000000000612 | PMID 31511329 Get It

Experience With a Research and Innovation Office to Support Laboratory Medicine and Pathology Research
Beinborn, Julie, Saling, Kenneth, Reed, Katelyn A. , Ibrahim, Mohamed , Feldman, Andrew L.

Mayo Clinic

American Journal of Clinical Pathology | September 11, 2019 | Volume: 152 | Issue: Supplement_1 | Pages: S99-S99

10.1093/ajcp/aqz119.001 Get It

Abstract Objectives Translational research in laboratory medicine and pathology is transforming health care based on recent quantum advances in omics technologies, computational science, and precision medicine. However, high-volume clinical settings where this research may be most effective often have significant constraints on faculty time that challenge productivity. The objective of this study was to assess our experience with a new resource designed to address this challenge. Methods In September 2016, we established the Research and Innovation Office (RIO) in the Department of Laboratory Medicine and Pathology, Mayo Clinic–Rochester. The goal was to provide infrastructure to unburden faculty from performing administrative, organizational, and operational tasks related to research. Over 30 months, we solicited faculty input into desired services, conducted surveys on utility and ease of use, and tracked metrics, including faculty participation, numbers of projects, and publications. Results Faculty members were highly satisfied with the range of services, ease of use, and service-oriented approach of RIO. Initial services included project organization, institutional process support (eg, IRB protocol management), biospecimen requests and handling, and data management. Based on early feedback, patient consenting, budget support, and manuscript assistance were added as additional services. Total RIO staff increased from 6 to 10 during in the first 30 months. Over this time, 97 of 160 faculty members (60%) utilized RIO services in over 1,000 discrete project requests. Annual departmental publications increased by 50% during this time. Conclusion Faculty time is a critical element for translational research productivity in laboratory medicine and pathology departments. Numerous tasks previously performed by faculty could be managed effectively by a team of research facilitators that unburdened constraints on research time and led to high levels of faculty engagement, satisfaction, and productivity. This model may promote advances in transformative laboratory medicine and pathology research in high-volume clinical settings.
CKD: A Call for an Age-Adapted Definition
Delanaye, Pierre , Jager, Kitty J. , Christensson, Anders , Dubourg, Laurence , Eriksen, Björn O. , Gaillard, F. , Gambaro, Giovanni , Giet, Markus van der , Glassock, Richard J. , Indridason, Ólafur S. , Londen, Marco van , Mariat, Christophe , Melsom, Toralf , Pottel, Hans , Schäeffner, Elke , Taal, Maarten W. , White, Christine A. , Grubb, Anders , Christensson, Anders , Eriksen, Bjørn Odvar , Nordin, Gunnar , Rule, Andrew D , Taal, Maarten W , Grubb, Anders , Delanaye, Pierre , Gaillard, Francois , Schaeffner, Elke , van Londen, Marco , Bökenkamp, Arend , Moranne, Olivier P. , Nordin, Gunnar , Pálsson, Runólfur , Rule, Andrew D. , Brand, Jan A.J.G. van den , Jager, Kitty J

Mayo Clinic

Journal of the American Society of Nephrology | September 10, 2019 | Volume: 30 | Issue: 10 | Pages: 1785-1805

10.1681/asn.2019030238 | PMID 31506289 Get It

Current criteria for the diagnosis of CKD in adults include persistent signs of kidney damage, such as increased urine albumin-to-creatinine ratio or a GFR below the threshold of 60 ml/min per 1.73 m 2 . This threshold has important caveats because it does not separate kidney disease from kidney aging, and therefore does not hold for all ages. In an extensive review of the literature, we found that GFR declines with healthy aging without any overt signs of compensation (such as elevated single-nephron GFR) or kidney damage. Older living kidney donors, who are carefully selected based on good health, have a lower predonation GFR compared with younger donors. Furthermore, the results from the large meta-analyses conducted by the CKD Prognosis Consortium and from numerous other studies indicate that the GFR threshold above which the risk of mortality is increased is not consistent across all ages. Among younger persons, mortality is increased at GFR <75 ml/min per 1.73 m 2 , whereas in elderly people it is increased at levels <45 ml/min per 1.73 m 2 . Therefore, we suggest that amending the CKD definition to include age-specific thresholds for GFR. The implications of an updated definition are far reaching. Having fewer healthy elderly individuals diagnosed with CKD could help reduce inappropriate care and its associated adverse effects. Global prevalence estimates for CKD would be substantially reduced. Also, using an age-specific threshold for younger persons might lead to earlier identification of CKD onset for such individuals, at a point when progressive kidney damage may still be preventable.
The Use of Vertical Rectus Abdominis Myocutaneous Flap for Pelvic Reconstruction: What Are the Risk Factors for Complications?
Kreutz‐Rodrigues, Lucas , Banuelos, Joseph, Saleem, Humza Y. , Mills, Andrew , Tran, Nho V. , Bakri, Karim

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | September 10, 2019 | Volume: 7 | Issue: 8S-1 | Pages: 75-75

10.1097/01.gox.0000584640.41927.51 Get It

Image Artifact Management for Clinical Magnetic Resonance Imaging on a 7 T Scanner Using Single-Channel Radiofrequency Transmit Mode
Fagan, Andrew , Welker, Kirk M. , Amrami, Kimberly K. , Frick, Matthew A., Watson, Robert E. , Kollasch, Peter , Chebrolu, Venkata V. , Felmlee, Joel P. , Fagan, Andrew J

Mayo Clinic

Investigative Radiology | September 10, 2019 | Volume: 54 | Issue: 12 | Pages: 781-791

10.1097/rli.0000000000000598 | PMID 31503079 Get It

Objectives The aim of this work was to devise mitigation strategies for addressing a range of image artifacts on a clinical 7 T magnetic resonance imaging scanner using the regulatory-approved single-channel radiofrequency transmit mode and vendor-supplied radiofrequency coils to facilitate clinical scanning within reasonable scan times. Materials and Methods Optimized imaging sequence protocols were developed for routine musculoskeletal knee and neurological imaging. Sources of severe image nonuniformities were identified, and mitigation strategies were devised. A range of custom-made high permittivity dielectric pads were used to compensate for B1 + and B1 − inhomogeneities, and also for magnetic susceptibility-induced signal dropouts particularly in the basal regions of the temporal lobes and in the cerebellum. Results Significant improvements in image uniformity were obtained using dielectric pads in the knee and brain. A combination of small voxels, reduced field of view B0 shimming, and high in-plane parallel imaging factors helped to minimize signal loss in areas of high susceptibility-induced field distortions. The high inherent signal-to-noise ratio at 7 T allowed for high receiver bandwidths and thin slices to minimize chemical shift artifacts. Intermittent artifacts due to radiofrequency inversion pulse limitations (power, bandwidth) were minimized with dielectric pads. A patient with 2 implanted metallic cranial fixation devices located within the radiofrequency transmit field was successfully imaged, with minimal image geometric distortions. Conclusions Challenges relating to severe image artifacts at 7 T using single-channel radiofrequency transmit functionality in the knee and brain were overcome using the approaches described in this article. The resultant high diagnostic image quality paves the way for incorporation of this technology into the routine clinical workflow. Further developmental efforts are required to expand the range of applications to other anatomical areas, and to expand the evidence- and knowledge-base relating to the safety of scanning patients with implanted metallic devices.
Digital-resolution detection of microRNA with single-base selectivity by photonic resonator absorption microscopy
Canady, Taylor D., Li, Nantao , Smith, Lucas D. , Lu, Yi , Smith, Andrew M. , Cunningham, Brian T. , Kohli, Manish , Smith, A M , Cunningham, Brian T

Mayo Clinic

Proceedings of the National Academy of Sciences | September 9, 2019 | Volume: 116 | Issue: 39 | Pages: 19362-19367

10.1073/pnas.1904770116 | PMID 31501320 Get It

Significance Highly selective and sensitive detection of microRNA is a key challenge in the development of liquid-biopsy approaches. Technologies that can achieve high diagnostic performance without the requirement of complicated processing steps or expensive equipment are necessary for broad use. With these features in mind, we demonstrate a digital-readout microRNA diagnostic that fundamentally relies on microRNA-activated nanoparticle-photonic crystal hybrid coupling. The hybrid formation allows for clear detection of single-particle binding events due to enhanced nanoparticle absorption at the binding location. Whereas the applied photonics lend the assay concentration sensitivity, we additionally demonstrate broad placement single-base mismatch selectivity and complex media detection by applying free-energy tuned toehold probes.
Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
Koach, Jessica , Holien, Jessica K. , Massudi, Hassina, Carter, Daniel R. , Ciampa, Olivia C. , Herath, Mika, Lim, Taylor, Seneviratne, Janith A. , Milazzo, Giorgio , Murray, Jayne , McCarroll, Joshua A. , Liu, Bing , Mayoh, Chelsea , Keenan, Bryce, Stevenson, Brendan W., Gorman, Michael A. , Bell, Jessica L. , Hüttelmaier, Stefan , Oberthuer, André , Fischer, Matthias , Gifford, Andrew J. , Liu, Tao , Zhu, Shizhen , Gustafson, W. Clay , Haber, Michelle , Fletcher, Jamie I. , Perini, Giovanni , Parker, Michael W. , Cheung, Belamy B. , Marshall, Glenn M. , Zhang, Xiaoling , Haber, Michelle , Norris, Murray D , Fletcher, Jamie I , Parker, Michael W , Doughty, Larissa , Zhang, Xiaoling

Mayo Clinic

Cancer Research | September 9, 2019 | Volume: 79 | Issue: 21 | Pages: 5652-5667

10.1158/0008-5472.can-19-1112 | PMID 31501192 Get It

Abstract MYCN is a major driver for the childhood cancer, neuroblastoma, however, there are no inhibitors of this target. Enhanced MYCN protein stability is a key component of MYCN oncogenesis and is maintained by multiple feedforward expression loops involving MYCN transactivation target genes. Here, we reveal the oncogenic role of a novel MYCN target and binding protein, proliferation-associated 2AG4 (PA2G4). Chromatin immunoprecipitation studies demonstrated that MYCN occupies the PA2G4 gene promoter, stimulating transcription. Direct binding of PA2G4 to MYCN protein blocked proteolysis of MYCN and enhanced colony formation in a MYCN-dependent manner. Using molecular modeling, surface plasmon resonance, and mutagenesis studies, we mapped the MYCN–PA2G4 interaction site to a 14 amino acid MYCN sequence and a surface crevice of PA2G4. Competitive chemical inhibition of the MYCN–PA2G4 protein–protein interface had potent inhibitory effects on neuroblastoma tumorigenesis in vivo. Treated tumors showed reduced levels of both MYCN and PA2G4. Our findings demonstrate a critical role for PA2G4 as a cofactor in MYCN-driven neuroblastoma and highlight competitive inhibition of the PA2G4-MYCN protein binding as a novel therapeutic strategy in the disease. Significance: Competitive chemical inhibition of the PA2G4–MYCN protein interface provides a basis for drug design of small molecules targeting MYC and MYCN-binding partners in malignancies driven by MYC family oncoproteins.
OS7.4 Calculating the net clinical benefit in brain tumor clinical trials by combining survival and health-related quality of life data using two methods: quality adjusted survival effect sizes (QASES) and joint modelling (JM)
Coomans, Marijke B , Bottomley, Andrew , Bent, Martin J. van den , Sloan, Jeff A. , Reijneveld, Jaap C. , Taphoorn, Martin , Baumert, Brigitta G. , Coens, Corneel , Gorlia, T., Herrlinger, Ulrich , Keime-Guibert, Florence, Martinelli, Francesca , Talacchi, Andrea , van den Bent, Martin J , Dirven, Linda , Stupp, Roger , Weller, Michael , Aaronson, Neil K. , Brandes, Alba Ariela , Chinot, Olivier , Gorlia, Thierry, Malmström, Annika , Wick, Wolfgang

Mayo Clinic

Neuro-Oncology | September 6, 2019 | Volume: 21 | Issue: Supplement_3 | Pages: iii14-iii15

10.1093/neuonc/noz126.047 Get It

Abstract BACKGROUND The impact of treatment on both the quality and the quantity of life, i.e. the ‘net clinical benefit’, should be considered to inform glioma patients and facilitate shared decision making. We applied two methods (i.e. Quality Adjusted Effect Sizes (QASES) and Joint Modelling (JM)) that combine survival and health-related quality of life (HRQoL) data into one outcome, to gain insight in the net clinical benefit of a treatment strategy. In addition, we assessed if both methods result in similar interpretations. MATERIAL AND METHODS We calculated the net clinical benefit in one randomized controlled trial, EORTC 26951 comparing radiotherapy (RT) + PCV chemotherapy versus RT alone, as a proof of concept for other trials. With the QASES method, effect sizes for differences in survival and HRQoL between treatment arms were calculated. Next, the combined effect size can be determined by weighing the emphasis put on survival or HRQoL (e.g. survival more important). JM allows simultaneous modeling of a longitudinal outcome (HRQoL), and a time-to event outcome (survival). HRQoL scales/items that were selected for primary analysis in the main study were also selected for this analysis: fatigue, global health, social functioning, communication deficit, seizures, physical functioning, and nausea/vomiting. RESULTS 288/386 patients completed baseline HRQoL forms and were included in the analysis. Overall survival (OS) was significantly longer with combined treatment (difference of 10.8 months). In contrast, the percentage of patients who experienced a clinically relevant deterioration (≥10 points) in nausea/vomiting, fatigue, social functioning and global health up to one year after treatment compared to baseline was larger in the RT+PCV arm. The QASES corresponded to a reduction in the median OS difference from 10.8 months to 6.8 months when adjusted for the HRQoL scales/items, when given equal weights to OS and HRQoL. JM analyses resulted in a theoretical loss of treatment effect in OS of 2–6% when adjusting for HRQoL. CONCLUSION Both methods showed that adjusting for the impact of treatment on a relevant HRQoL parameter reduced the survival benefit in the experimental treatment arm compared to standard treatment arm. Applying these methods may facilitate communicating the impact of treatment to patients in clinical practice.